DK155143C - Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet - Google Patents

Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Info

Publication number
DK155143C
DK155143C DK420385A DK420385A DK155143C DK 155143 C DK155143 C DK 155143C DK 420385 A DK420385 A DK 420385A DK 420385 A DK420385 A DK 420385A DK 155143 C DK155143 C DK 155143C
Authority
DK
Denmark
Prior art keywords
breast
pct
treatment
antioestrogent
boney
Prior art date
Application number
DK420385A
Other languages
English (en)
Other versions
DK155143B (da
DK420385D0 (da
DK420385A (da
Inventor
Pierre Mauvais-Jarvis
Frederique Kuttenn
Original Assignee
Mauvais Jarvis Pierre
Frederique Kuttenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre
Publication of DK420385D0 publication Critical patent/DK420385D0/da
Publication of DK420385A publication Critical patent/DK420385A/da
Publication of DK155143B publication Critical patent/DK155143B/da
Application granted granted Critical
Publication of DK155143C publication Critical patent/DK155143C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK420385A 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet DK155143C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8400927A FR2558373B1 (fr) 1984-01-20 1984-01-20 Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
FR8400927 1984-01-20
EP8400436 1984-12-21
PCT/EP1984/000436 WO1985003228A1 (fr) 1984-01-20 1984-12-21 Medicament antioestrogene pour administration percutanee

Publications (4)

Publication Number Publication Date
DK420385D0 DK420385D0 (da) 1985-09-17
DK420385A DK420385A (da) 1985-09-17
DK155143B DK155143B (da) 1989-02-20
DK155143C true DK155143C (da) 1989-07-03

Family

ID=9300348

Family Applications (1)

Application Number Title Priority Date Filing Date
DK420385A DK155143C (da) 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Country Status (8)

Country Link
US (1) US4919937A (da)
EP (2) EP0151326B1 (da)
JP (1) JPH0667826B2 (da)
AT (1) ATE73334T1 (da)
DE (1) DE3485581D1 (da)
DK (1) DK155143C (da)
FR (1) FR2558373B1 (da)
WO (1) WO1985003228A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
WO1990010462A1 (en) * 1989-03-10 1990-09-20 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
US5119827A (en) * 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
ES2156361T5 (es) 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
US20020086856A1 (en) 1998-03-18 2002-07-04 Alfred Schmidt Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
FI982733A (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
CA2409765A1 (en) 2000-05-10 2001-11-15 David A. Sirbasku Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US7863011B2 (en) * 2000-05-10 2011-01-04 Signe Biopharma, Inc. Screening method for predicting susceptibility to breast cancer
US8119138B2 (en) * 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
EP1515748A4 (en) * 2001-11-14 2006-04-12 David A Sirbasku ANTIESTROGEN AND IMMUNOMODULATOR COMBINATIONS FOR THE TREATMENT OF BREAST CANCER
AU2002366800B2 (en) 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
SI1572178T1 (sl) * 2002-12-18 2006-10-31 Besins Int Lab Zdravljenje mastalgije s 4-hidroksi-tamoksifenom
WO2004054558A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
AU2004203700B2 (en) * 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
ES2483896T3 (es) 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
CA2528431C (en) * 2003-06-09 2012-09-18 Northwestern University Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1550440A1 (en) * 2003-12-15 2005-07-06 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
WO2005058297A1 (en) * 2003-12-15 2005-06-30 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PT1748770E (pt) * 2004-03-22 2008-07-16 Besins Int Lab Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
KR100850910B1 (ko) * 2006-12-22 2008-08-07 삼성전자주식회사 블루투스 디바이스를 연결하기 위한 장치 및 방법
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires

Also Published As

Publication number Publication date
WO1985003228A1 (fr) 1985-08-01
DE3485581D1 (de) 1992-04-16
FR2558373B1 (fr) 1987-07-03
ATE73334T1 (de) 1992-03-15
EP0151326B1 (fr) 1989-07-12
DK155143B (da) 1989-02-20
EP0169214A1 (fr) 1986-01-29
JPS61500914A (ja) 1986-05-08
EP0151326A1 (fr) 1985-08-14
EP0169214B1 (fr) 1992-03-11
DK420385D0 (da) 1985-09-17
US4919937A (en) 1990-04-24
JPH0667826B2 (ja) 1994-08-31
FR2558373A1 (fr) 1985-07-26
DK420385A (da) 1985-09-17

Similar Documents

Publication Publication Date Title
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
PT799209E (pt) Novas sulfonamidas
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69229050D1 (de) Verwendung von Papillomavirusprotein L2 zur therapeutischen Behandlung von durch Papillomavirus hervorgerufenen Tumoren oder oder anderen krankhaften Veränderungen
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
HUT74674A (en) Use of modafinil for preparing pharmaceutica compositions for the treatment of sleep apnoea and ventilation problems of central origin
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
ES482723A1 (es) Un procedimiento para la obtencion de una composicion de clotrimazol
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
JPS57122085A (en) Circulatory disease extirpenter and use
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
BR0113461A (pt) Compostos ou sais farmaceuticamente aceitáveis, composições farmacêuticas, método de tratamento de doença ou condição mediada por erab, hadh2 ou (beta)-amilóide em mamìferos, métodos de inibição ou modulação da atividade enzimática de erab ou hadh2 e método de tratamento de mal de alzheimer ou demência em mamìferos
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
BR8008818A (pt) Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
DK12388A (da) Sialosylcholesterol, fremgangsmaade til fremstilling af og neuropatimiddel omfattende samme
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES8106498A1 (es) Un procedimiento para la preparacion de derivados del pirrol
PT98764A (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos